Cargando…
COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781039/ https://www.ncbi.nlm.nih.gov/pubmed/36555978 http://dx.doi.org/10.3390/jcm11247361 |
_version_ | 1784856975973023744 |
---|---|
author | Castonguay, Mathias Dakhallah, Nawar Desroches, Justin Colaiacovo, Marie-Laure Jimenez-Cortes, Camille Claveau, Anne-Marie Bérubé, Samuel Hafsaoui, Amer Yassine Souza, Amalia Tibout, Pauline Ah-Yan, Christophe Vincent, Anne-Marie Naessens, Veronique Brossard, Josée Abish, Sharon Santiago, Raoul Soulières, Denis Laroche, Vincent Pastore, Yves Tran, Thai Hoa Forté, Stéphanie |
author_facet | Castonguay, Mathias Dakhallah, Nawar Desroches, Justin Colaiacovo, Marie-Laure Jimenez-Cortes, Camille Claveau, Anne-Marie Bérubé, Samuel Hafsaoui, Amer Yassine Souza, Amalia Tibout, Pauline Ah-Yan, Christophe Vincent, Anne-Marie Naessens, Veronique Brossard, Josée Abish, Sharon Santiago, Raoul Soulières, Denis Laroche, Vincent Pastore, Yves Tran, Thai Hoa Forté, Stéphanie |
author_sort | Castonguay, Mathias |
collection | PubMed |
description | Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population. |
format | Online Article Text |
id | pubmed-9781039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97810392022-12-24 COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic Castonguay, Mathias Dakhallah, Nawar Desroches, Justin Colaiacovo, Marie-Laure Jimenez-Cortes, Camille Claveau, Anne-Marie Bérubé, Samuel Hafsaoui, Amer Yassine Souza, Amalia Tibout, Pauline Ah-Yan, Christophe Vincent, Anne-Marie Naessens, Veronique Brossard, Josée Abish, Sharon Santiago, Raoul Soulières, Denis Laroche, Vincent Pastore, Yves Tran, Thai Hoa Forté, Stéphanie J Clin Med Article Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population. MDPI 2022-12-12 /pmc/articles/PMC9781039/ /pubmed/36555978 http://dx.doi.org/10.3390/jcm11247361 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Castonguay, Mathias Dakhallah, Nawar Desroches, Justin Colaiacovo, Marie-Laure Jimenez-Cortes, Camille Claveau, Anne-Marie Bérubé, Samuel Hafsaoui, Amer Yassine Souza, Amalia Tibout, Pauline Ah-Yan, Christophe Vincent, Anne-Marie Naessens, Veronique Brossard, Josée Abish, Sharon Santiago, Raoul Soulières, Denis Laroche, Vincent Pastore, Yves Tran, Thai Hoa Forté, Stéphanie COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic |
title | COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic |
title_full | COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic |
title_fullStr | COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic |
title_full_unstemmed | COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic |
title_short | COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic |
title_sort | covid-19 and sickle cell disease in the province of quebec, canada: outcomes after two years of the pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781039/ https://www.ncbi.nlm.nih.gov/pubmed/36555978 http://dx.doi.org/10.3390/jcm11247361 |
work_keys_str_mv | AT castonguaymathias covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT dakhallahnawar covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT desrochesjustin covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT colaiacovomarielaure covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT jimenezcortescamille covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT claveauannemarie covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT berubesamuel covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT hafsaouiameryassine covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT souzaamalia covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT tiboutpauline covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT ahyanchristophe covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT vincentannemarie covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT naessensveronique covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT brossardjosee covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT abishsharon covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT santiagoraoul covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT soulieresdenis covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT larochevincent covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT pastoreyves covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT tranthaihoa covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic AT fortestephanie covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic |